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dimvastatin and
laque Inflammation
e read with great interest the study by Tahara et al. (1) published
ecently in the Journal and concerned with tracking statin-induced
nflammation reduction in atherosclerotic plaques using fluorode-
xyglucose positron emission tomography (FDG-PET).
Although this study highlights the very real potential of
DG-PET imaging of atherosclerosis for the detection and
onitoring of plaque inflammation, we would like to comment on
everal aspects of the study’s methodology that may have impacted
he results seen by the investigators.
First, we believe that the time between injection of FDG and
ET image acquisition was too short at 1 h. Previous studies have
hown that a circulation time for FDG in excess of 2 h gives a
uch higher target (plaque)-to-background (blood) ratio (2–4). A
igh target-to-blood ratio is crucial to ensuring proper region-of-
nterest placement and thus accurate quantification of plaque FDG
ptake.
Second, especially given their choice of early imaging time
oint, the researchers should have attempted to correct the plaque
DG uptake for blood activity. This is typically achieved by
easurement of the mean of several blood values from a large vein.
his value is then divided into the plaque standardized uptake
alue to yield a tissue-to-blood ratio of FDG uptake. This is the
ethod adopted in previous studies, and in the elegant study by
awakol et al. (2) which appears in the same issue of the Journal.
lthough Tahara et al. (1) defend their decision not to do this, we
o not believe the reasons they give justify the absence of a
orrection. The investigators suggest that the patchy uptake of
ascular FDG and the nonvisualization of veins means that the
lood-pool signal is likely insignificant. More likely is the fact that
therosclerosis is a diffuse condition, taking up FDG variably along
he length of the vessel. Additionally, we believe that blood-pool
ctivity would still be significant at such an early imaging time
oint, with a standardized uptake value well above other back-
round structures.
Additionally, we suggest the use of a combined PET/computed
omography scanner may have made accurate anatomical coregis-
ration easier. This will be particularly important when extending
his kind of study into the aorta and other vascular beds.
Finally, we contend that the investigators might have chosen a
ore potent anti-inflammatory drug than low-dose simvastatin for
esting their hypothesis that FDG-PET imaging could track
nflammatory change within plaque. Although their study yielded
ositive results, the magnitude of the effect would surely have been
reater with a higher dose of a more powerful statin, and this
ight have answered some of the questions with which the
esearchers were left at the end of their study, such as why the
DG reduction induced by statin treatment correlated more
losely with the high-density lipoprotein increase than with
ow-density lipoprotein decrease. vTahara et al. (1) should be congratulated on completing such an
xciting piece of work, but we suggest that for future studies in this
rea a longer FDG circulation time with appropriate blood activity
orrection should be used. If these ideas had been adopted by the
nvestigators in their current study, we believe they would have
hown an even greater positive impact of the statin upon plaque
nflammation as assessed by FDG-PET.
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e thank Drs. Rudd, Machac, and Fayad for having interest in
ur recent study (1). There is a growing body of evidence that
uorodeoxyglucose positron emission tomography (FDG-PET)
maging has a great potential for noninvasively detecting and
uantifying plaque inflammation in humans. Anecdotal studies
ave reported increased FDG uptake in the regions of the aorta
nd large arteries in patients who had undergone FDG-PET
maging for cancer diagnosis and staging (2,3). Recently, we and
thers have validated FDG uptake in the arterial wall (i.e., plaques)
y coregistering FDG-PET imaging with structural imaging, such
s computed tomography and magnetic resonance imaging
1,4–7). More importantly, histological examination of the end-
rterectomized specimen obtained from the FDG uptake-
ocumented carotid arteries has provided solid evidence that the
ascular FDG uptake is associated with macrophage accumulation,
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May 15, 2007:1991–2amely plaque inflammation, not only in symptomatic but also
symptomatic carotid plaques, irrespective of the severity of the
uminal stenosis (5–7). In addition, our recent study has revealed
hat FDG-PET imaging is a practical tool to monitor the
ffectiveness of anti-inflammation therapy for atherosclerotic dis-
ases (1).
Because of limited time available for PET imaging for patients
n our institution, PET imaging was performed 1 h after FDG
njection. We agree that longer time may provide clearer PET
maging. Standardized uptake value (SUV) of the juglar vein
blood uptake) was low and almost constant in our study. Thus, we
id not normalize SUV of the plaque by blood SUV. However, we
gree that normalization may give more accurate identification of
nflamed plaques. The dose of FDG administered, the duration
etween FDG injection and PET image acquisition, and the
ethod of quantification of FDG uptake should be standardized
efore this modality is widely applied for clinical practice, espe-
ially for plaque inflammation imaging. The use of a combined
ET/computed tomographic scanner will improve the accuracy of
he anatomical diagnosis of plaque FDG uptake. Also, more
acrophage-specific PET tracer is desirable to image plaques in
etabolically active tissues such as the heart and brain.
Considering the future direction, it would be interesting to study 1)
he prevalence of inflammation of the documented plaques, 2) risk
actors contributing to plaque inflammation, and 3) whether more
owerful statins would show greater reduction in plaque inflammation
r whether other potentially anti-inflammatory drugs, such as angio-
ensin receptor blockers, would decrease FDG uptake in inflamed
laques. A prospective study with a large number of patients is
arranted to elucidate whether vascular FDG uptake can be a
redictor of cardiovascular events. Finally, the comments made by
udd et al. will be very helpful in making FDG-PET imaging
linically more useful in future studies.Hisashi Kai, MD, PhD
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